Free Trial
NASDAQ:ATYR

Atyr PHARMA Q2 2023 Earnings Report

Atyr PHARMA logo
$3.24 -0.04 (-1.22%)
Closing price 04:00 PM Eastern
Extended Trading
$3.30 +0.05 (+1.70%)
As of 04:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atyr PHARMA EPS Results

Actual EPS
-$0.22
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

Atyr PHARMA Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Atyr PHARMA Announcement Details

Quarter
Q2 2023
Time
N/A
Conference Call Date
Wednesday, August 9, 2023
Conference Call Time
4:00PM ET

Atyr PHARMA Earnings Headlines

Watch This Robotics Demo Before July 23rd
Jeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."
Atyr PHARMA FY2026 EPS Forecast Reduced by HC Wainwright
See More Atyr PHARMA Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Atyr PHARMA? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Atyr PHARMA and other key companies, straight to your email.

About Atyr PHARMA

Atyr PHARMA (NASDAQ:ATYR), Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

View Atyr PHARMA Profile

More Earnings Resources from MarketBeat